cagrilintide and semaglutide blend (5 mg) + (5 mg) CagriSema Dosage Protocol: Research Reference

P., Iqbal, H

Rights and permissions About this article Cite this article Loeser, R., Collins, J

Anyone claiming dramatic physical transformation in the first two weeks is either exaggerating, responding to placebo effect, or attributing unrelated changes to the peptides

JAMA Internal Medicine, 173 (5), 355-361

CONTRAINDICATIONS History of hypersensitivity reaction to tirzepatide or any of its excipients Personal or family history of medullary thyroid carcinoma (MTC) Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) PRECAUTIONS Kidney disease No dose adjustment is recommended in patients with any degree of renal impairment Liver disease No dose adjustment is recommended in patients with any degree of liver disease Stomach disorders Tirzepatide slows gastric emptying and is not recommended in patients with significant stomach disorders, including diabetic gastroparesis General anesthesia or deep sedation GLP-1 therapies, like tirzepatide, slow gastric emptying, possibly increasing the risk of residual gastric contents and pulmonary aspiration in patients receiving anesthesia or deep sedation for procedures